Clinical Trials Logo

Filter by:
NCT ID: NCT05873270 Active, not recruiting - Clinical trials for Postoperative Nausea and Vomiting

Randomized, Controlled, Single-blind Exploratory Study of the Efficacy and Safety of Wrist and Ankle Acupuncture Intervention on Nausea, Vomiting and Pain After Sleeve Gastric Surgery in Women

Start date: March 23, 2023
Phase:
Study type: Observational

PONV is the most common clinical presentation after surgical procedures beyond pain. A retrospective study of our center found that the postoperative incidence of LSG was 77.4%. PONV can not only cause postoperative discomfort, but also cause serious complications such as disturbance water and electrolyte balance, wound splitting, incisional hernia, and even residual gastric leakage and aspiration pneumonia, resulting in prolonged hospital stay and increased medical costs. Wrist and ankle acupuncture is a special kind of acupuncture therapy. Through subcutaneous stimulation, the electrical signal is fed back along the nerve fiber into the cerebral cortex, without dialectical treatment, and only needs the appropriate symptoms and signs of the patient. Although only in the wrist and ankle, it can solve a series of problems in the whole body, especially nausea, vomiting and pain symptoms.

NCT ID: NCT05872620 Active, not recruiting - Obesity Clinical Trials

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

ATTAIN-2
Start date: June 5, 2023
Phase: Phase 3
Study type: Interventional

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.

NCT ID: NCT05869903 Active, not recruiting - Obesity Clinical Trials

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

ATTAIN-1
Start date: June 5, 2023
Phase: Phase 3
Study type: Interventional

This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities.

NCT ID: NCT05869123 Active, not recruiting - Clinical trials for Endometrial Neoplasms

Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer

Start date: October 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Online adaptive radiotherapy (oART) has demonstrated to be feasible to reduce planning target volume (PTV) margins for postoperative treatment of endometrial and cervical cancer. To explore the value of reduced margins in oART for postoperative treatment of endometrial and cervical cancer, we conducted a prospective clinical trial to determine the clinical efficacy and toxicity of reduced margins.

NCT ID: NCT05868967 Active, not recruiting - Clinical trials for Phase 1 Study, Healthy Volunteers

A Clinical Study to Investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects

Start date: February 27, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects

NCT ID: NCT05865496 Active, not recruiting - Sinusitis Clinical Trials

A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Start date: June 30, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the effect and safety of 611 in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

NCT ID: NCT05859529 Active, not recruiting - Health Volunteer Clinical Trials

A Pharmacokinetic Study of JS002 in Healthy Subjects

Start date: May 30, 2023
Phase: Phase 1
Study type: Interventional

This study was a single-center, randomized, open-label, single-dose, parallel-controlled trial design conducted in healthy adult subjects. Subjects were randomly assigned to 1 of 2 parallel treatment groups: treatment group A received a single subcutaneous injection of JS002 150 mg via PFS, and treatment group B received a single subcutaneous injection of JS002 150 mg via AI. Subjects were followed up to study day 85 for pharmacokinetic equivalence assessment of JS002. A total of 159 subjects were planned to be included in each group. After signing the informed consent form and completing the screening examination, subjects will be randomly assigned to treatment arm A or treatment arm B if eligible for inclusion. The study period consisted of a screening period of up to 21 days and a follow-up period of 12 weeks (85 days). Subjects were admitted to the phase I clinical research unit the day before dose administration (day 1) and were not allowed to leave until all examinations and assessments were completed on day 6 after dose administration and were allowed to return to the clinical research center for follow-up visits on days 8,11,15,22,29,43,57,71, and 85.

NCT ID: NCT05856578 Active, not recruiting - Clinical trials for Type 2 Diabetes Mellitus

Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 Diabetes

Start date: March 15, 2022
Phase: Phase 4
Study type: Interventional

The aim of the study is to investigate the efficacy and safety of Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet and Canagliflozin for 12 weeks in individuals with type 2 diabetes mellitus

NCT ID: NCT05856084 Active, not recruiting - Herpes Zoster Clinical Trials

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Start date: May 7, 2023
Phase: Phase 2
Study type: Interventional

The purposes of the study are to evaluate the immunogenicity and safety of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 30 years and older.

NCT ID: NCT05845034 Active, not recruiting - Atrial Fibrillation Clinical Trials

A New Theory of Electrophysiological Mechanism of Atrial Fibrillation

ANTEMAF
Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The electrophysiological mechanisms of atrial fibrillation remain disagreements. The goal of this clinical trail is to propose a new electrophysiological mechanism hypothesis of atrial fibrillation(AF),meanwhile, the investigators sought to test the hypothesis that the superposition electrograms (SPEs) recorded during atrial fibrillation could be used as target sites for catheter ablation of atrial fibrillation.